Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.

Ana Paula Costa,Paula Machado,Luanda Barbara Canário,Paulo Giraldo,Rand Randall Martins,Márcia Consolaro,José Eleutério Jr,Raquel Souza,Ricardo Cobucci,Ana Katherine Gonçalves,Pedro Vieira Baptista

doi:10.31557/apjcp.2020.21.9.2799

Abstract

Objective:The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. Methods:Serum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA. Results:The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infected women when compared to vaccinated women (p<0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74. Conclusion:The IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes.

Highlights

Human papillomavirus (HPV) is the most common sexually transmitted infection of the female reproductive tract which can be spread through direct sexual contact and is associated with a variety of clinical conditions that range from innocuous lesions to cancer (Veiga et al, 2020)
The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types
The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p

Summary

Introduction

Human papillomavirus (HPV) is the most common sexually transmitted infection of the female reproductive tract which can be spread through direct sexual contact and is associated with a variety of clinical conditions that range from innocuous lesions to cancer (Veiga et al, 2020). All available vaccines are based on non-infectious recombinant type specific L1 capsid proteins assembled into VLPs, acting as immunogens. These present an exterior surface closely mimicking HPV virions, and it is this multiplicity of L1 domains that stimulate a humoral immune response by exposing the system to VLPs, generating high neutralizing antibody titers 100 times higher than those occurring in natural infections (Gonçalves et al, 2016; Pinto et al, 2018)

Methods

Results

Conclusion